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Overthelast20years,anumberoftumor-speciﬁc chromosomaltranslocationsandassociatedfusiongeneshavebeen identiﬁedfor
mesenchymalneoplasmsincludingadipocytic tumors.Theadditionofmolecularcytogenetic techniques, especiallyﬂuorescencein
situhybridization(FISH), hasfurther enhanced the sensitivityandaccuracy ofdetecting nonrandomchromosomaltranslocations
and/or other rearrangements in adipocytic tumors. Indeed, most resent molecular cytogenetic analysis has demonstrated a
translocation t(11;16)(q13;p13) that produces a C11orf95-MKL2 fusion gene in chondroid lipoma. Additionally, it is well
recognized that supernumerary ring and/or giant rod chromosomes are characteristic for atypical lipomatous tumor/well-
diﬀerentiated liposarcoma and dediﬀerentiated liposarcoma, and ampliﬁcation of 12q13–15 involving the MDM2, CDK4,a n d
CPM genes is shown by FISH in these tumors. Moreover, myxoid/round cell liposarcoma is characterized by a translocation
t(12;16)(q13;p11) that fuses the DDIT3 and FUS genes. This paper provides an overview of the role of conventional cytogenetics
and molecular cytogenetics in the diagnosis of adipocytic tumors.
1.Introduction
Adipocytic tumors represent the largest group of soft tissue
tumors that have been studied by cytogenetic analysis.
In 1986, the ﬁrst consistent karyotypic abnormality was
discovered in adipocytic tumors [1–3]. The current World
Health Organization (WHO) classiﬁcation of adipocytic
tumors includes eleven benign, one intermediate, and ﬁve
malignant subtypes [4].
The diagnosis of adipocytic tumors is primarily based
on clinical features and histologic patterns. However, atyp-
ical lipomatous tumor/well-diﬀerentiated liposarcoma ded-
iﬀerentiated liposarcoma are often diﬃcult to distinguish
morphologically from benign adipocytic tumors and other
high-grade sarcomas, respectively. Immunohistochemistry
plays little role in the diﬀerential diagnosis of adipocytic
tumors [4]. Moreover, the use of minimally invasive biopsies
to diagnose adipocytic tumors has become increasingly
common, and this shift has created additional challenges. In
such instances, molecular genetic testing can serveas a useful
diagnostic adjunct for adipocytic tumors.
Most types of adipocytic tumor have distinctive cyto-
genetic aberrations which can be of considerable help in
diagnosis. This paper reviews the cytogenetic and molecular
cytogenetic characteristics of adipocytic tumors as well as
their clinicopathologic features. The consistent chromoso-
mal alterations are summarized in Table 1.
2.Methodsof Cytogeneticand Molecular
CytogeneticAnalyses
A soft tissue sample submitted for conventional cytogenetic
analysis must be fresh and should be representative of the
neoplastic process. Also, necrotic tissue should be dissected
from the sample. Generally, a 1-2cm3 fresh sample is
provided for cytogenetics [5]. The basic process of cell
culturing is the same for all adipocytic lesions. Brieﬂy, sterile
tumor tissue is minced with scissors and then disaggregated
with collagenase. The isolated cells are washed, diluted in
culture medium, and seeded in culture ﬂaks or chamber
slides. The cultures are incubated in a 5% CO2 atmosphere2 Journal of Biomedicine and Biotechnology
Table 1: Chromosomalaberrations and associated molecular events in adipocytic tumors.
Tumor type Chromosomalaberration Molecular event
Benign
Lipoma t(3;12)(q27-28;q13–15) HMGA2-LPP
t(9;12)(p22;q13–15) HMGA2-NFIB
t(2;12)(q37;q13–15) HMGA2-CXCR7
t(5;12)(q32-33;q13–15) HMGA2-EBF1
t(12;13)(q13–15;q12) HMGA2-LHFP
6p21–23 rearrangement HMGA1 rearrangement
13q deletion Not known
Chondroid lipoma t(11;16)(q13;p13) C11of95-MKL2
Spindle cell/pleomorphic lipoma 13q and/or 16q deletions Not known
Hibernoma 11q13 rearrangement MEN1, PPP1A deletion
Lipoblastoma 8q11–13 rearrangement PLAG1 rearrangement
Intermediate (locally aggressive)
Atypical lipomatous tumor/ Ring/giant marker chromosome MDM2, CDK4, CPM,
well diﬀerentiated liposarcoma (12q13–15 ampliﬁcation) HMGA2 ampliﬁcation
Malignant
Dediﬀerentiated liposarcoma Ring/giant marker
chromosome∗ MDM2, CDK4, CPM,
(12q13–15 ampliﬁcation) HMGA2 ampliﬁcation
Myxoid/round cell liposarcoma t(12;16)(q13;p11) FUS-DDIT3
t(12;22)(q13;q12) EWSR1-DDIT3
Pleomorphic liposarcoma Complex karyotype Not known
∗Dediﬀerentiated liposarcoma may contain complex aberrations in addition to ring or giant marker chromosomes.
at 37◦C. A short-term culturing usually results in a suﬃcient
number of mitoses within 5–10 days. Then, dividing cells
are arrested in metaphase by the addition of a mitotic-
spindle inhibitor such as colcemid. The cells are ﬁxed
with methanol/glacial acetic acid (3:1) and stained using a
trypsin-Giemsa method to produce characteristic banding
patterns. Ideally, 20 metaphase cells are analyzed for each
specimen.
During the last two decades, the ability to identify
chromosomal abnormalities has been markedly improved by
the development of molecular cytogenetic technologies such
asﬂuorescence in situ hybridization (FISH)and comparative
genomic hybridization (CGH). FISH is a technique that
involves detection of speciﬁc DNA sequences by hybridiza-
tion with complimentary DNA probes. A major advantage
of FISH is that nondividing (interphase) nuclei from fresh,
frozen, or formalin-ﬁxed samples can be evaluated. It has
been realized that FISH is an eﬀective adjunct in the
diagnosis of soft tissue tumors including adipocytic tumors
[6]. On the other hand, FISH cannot detect smaller genetic
alterations such as point mutations. Recently, multicolor
FISH(M-FISH)canbeusedtodetectcrypticrearrangements
or decipher the origin of marker chromosomes in complex
karyotypes [7]. The combination of chromosome banding
analysis with M-FISH has the potential to identify and
describe most karyotypic changes of sarcoma cells. CGH
is a technique for the analysis of DNA sequence copy
n u m b e rc h a n g e sa c r o s st h eg e n o m ei nas i n g l eh y b r i d i z a t i o n
experiment [8]. Brieﬂy, tumor (test) and reference (control)
DNAsarediﬀerentiallylabeledwithgreenorredﬂuorescence
dyes, mixed in a 1:1 ratio in the presence of human Cot-
1 DNA (to block repetitive sequences), and cohybridized to
normal metaphase chromosome spreads. Metaphase spreads
are captured using a high resolution or cooled charge-
coupled device camera, and the images are analyzed with
the CGH software. The sensitivity of CGH is restricted
by purity of the cell population and depends on the level
and size of the copy number changes. In addition, CGH
cannot detect rearrangements such as inversions or balanced
translocations. Recently, a higher resolution version ofCGH,
so-called array CGH, has been made available [9]. In this
novel technique, test and reference DNAs are diﬀerentially
labeled and competitively hybridized to glass slides (chips)
containing multiple DNA fragments. A distinct advantage
of array CGH is the ability to directly map the copy
number changes to the genome sequence. Moreover, low
c o p yn u m b e rg a i n sa n dl o s s e sc a nb ed e t e c t e db ya r r a yC G H
at a resolution about 100kb.
3.Benign AdipocyticTumors
3.1. Lipoma. Ordinary lipoma is the most common soft
tissue tumor and may appear at any site. It occurs mainly
in the ﬁfth to seventh decades of life, frequently in obese
individuals. Lipomas are rare in children. Approximately
5% of patients have multiple lipomas [4]. Ordinary lipomasJournal of Biomedicine and Biotechnology 3
present as painless, slowly growing soft tissue masses and
can arise within subcutaneous tissue or deep soft tissue.
Deep-seated lipomas (e.g., intramuscular or intermuscular
lipomas) are larger and grossly less well-deﬁned than their
subcutaneous counterparts and can mimic atypical lipoma-
tous tumor/well diﬀerentiated liposarcoma. Histologically,
the tumor is composed of lobules of mature fat cells which
vary slightly in size and shape.
Clonal cytogenetic aberrations have been identiﬁed in
nearly 60% of ordinary lipomas [4, 10–12]. The 12q13–15
region is the most commonly involved in such aberrations,
followedby6p21–23and13q[10,13,14].This chromosomal
region recombines with a large variety of other chromosome
bands through translocations. The most frequent transloca-
tion is t(3;12)(q27-28;q13–15) that fuses the HMGA2 and
LPP genes [15]. HMGA2 has also been reported to form
fusion genes with CXCR7 (at 2q37), EBF1 (at 5q33), NFIB
(at 9p22), and LHFP (at 13q12) [16–20]. Rearrangements of
HMGA2 can be identiﬁed by FISH analysis [14, 17, 21, 22],
but these probes are not widely available. About 15%–20%
of ordinary lipomas show rearrangements or deletions of the
longarmofchromosome13,inparticular13q12–22[14,23].
Moreover, FISH analysis has revealed that chromosome 13
is involved in a variety of rearrangements and deletions
that cover a limited segment (∼2.5Mb) of chromosome
band 13q14, distal to the RB1 gene [23]. Rearrangements
of 6p21–23 involving the HMGA1 gene has been described
in ordinary lipomas without 12q13–15 aberrations [10, 14].
Recently, Wang et al. [24] detected the presence of an
HMGA1-LPP/TPRG1 gene fusion in an ordinary lipoma
with t(3;6)(q27;p21). A CGH study has indicated that no
copy number changes are found in ordinary lipomas, and
this technique may help in the diﬀerential diagnosis of
intermediate adipocytic tumors [25].
3.2. Chondroid Lipoma. Chondroid lipoma is a distinctive
tumor composed of strands and nests of lipoblasts and
mature fat cells in a variably myxoid or myxochondroid
matrix. This tumor occurs predominantly in the proximal
extremities and limb girdles of middle-aged adults. Chon-
droid lipoma may be mistaken for several other benign and
malignant soft tissue tumors such as myxoid liposarcoma or
extraskeletal myxoid chondrosarcoma [12].
A reciprocal translocation t(11;16)(q13;p13) has been
found in six chondroid lipoma cases [26–29]. Most recently,
Huang et al. [29] reported that this chromosomal transloca-
tion results in a fusion of C11orf95 and MKL2. The presence
of the t(11;16) or the C11orf95-MKL2 fusion transcript is
highly speciﬁc for chondroid lipoma, and is absent in any
other related tumors. Therefore, an analysis of C11orf95 or
MKL2rearrangement using FISHis usefulforthe diﬀerential
diagnosis of chondroid lipoma and its histologic mimickers.
3.3. Spindle Cell Lipoma/Pleomorphic Lipoma. Spindle cell
and pleomorphic lipomas are histologic ends of a spectrum
of a single clinicopathologic entity and supported by cytoge-
netic evidence [4]. These tumors present as circumscribed
subcutaneous lesions occurring typically on the neck and
upper back, particularly older males. Histologically, spindle
cell lipoma is composed of a mixture of mature fat cells
and small spindle cells associated with a myxoid matrix
and collagen bundles. In the other end of the spectrum,
pleomorphiclipomaischaracterizedbythepresenceofmult-
inucleatedﬂoret-likegiantcells.Immunohistochemically,the
spindle cells in both spindle cell and pleomorphic lipomas
are strongly positive for CD34 [4].
Spindle cell and pleomorphic lipomas show similar
cytogenetic aberrations which are usually more complex
than ordinary lipomas. The karyotypes of these tumors
are frequently hypodiploid with multiple partial deletions
and few balanced rearrangements. The recurrent cytogenetic
aberrations appear to be deletion of 16q13-qter, monosomy
for chromosome 13, or partial deletion of 13q [30–32].
However, it should be kept in mind that deletions and
structural rearrangements of 13q have been described in
other adipocytic tumors [23].
3.4. Hibernoma. Hibernoma is rare, benign adipocytic
tumor composed of brown fat cells with granular, multi-
vacuolated cytoplasm. The tumor occurs primarily in the
thigh and scapular and interscapular regions of young
adults.Incaseswithnumerousunivacuolatedcells,histologic
distinction from ordinary lipoma may be diﬃcult. Also,
hibernoma may be misdiagnosed as well diﬀerentiated or
myxoid liposarcoma because of the paucity of diagnostic
brown fat cells in the lipoma-like or myxoid variant [12].
Hibernomas have near or pseudodiploid karyotypes
which are frequently somewhat more complex than ordinary
lipomas. They are characterized by structural rearrange-
ments involving the long arm of chromosome 11, in particu-
lar 11q13. No chromosomal band has been involved more
than once as a translocation partner [4]. Metaphase FISH
analyses have demonstrated that homozygousdeletion of the
MEN1 tumorsuppressorgene (at11q13.1)andheterozygous
deletion of PPP1CA (distal to MEN1 at 11q13) are found in
hibernomas [33]. Recently,Maire etal. [34]reported thatthe
altered region at11q13islargerthan previouslyreported and
rearrangements of GARP (at 11q13.5) or a neighboring gene
may be important in the pathogenesis of hibernomas.
3.5. Lipoblastoma. Lipoblastoma occurs predominantly in
c h i ldr eny oun gerth a n3y ea r sofa ge.I tpr es en tsa saloca li z ed
(lipoblastoma) or diﬀuse (lipoblastomatosis) tumor, resem-
bling fetal white adipose tissue. The extremities are the most
common site, but many other locations can be involved
[4]. Histologically, lipoblastoma shows a lobular appearance
and is composed of an admixture of mature adipocytes and
lipoblasts in diﬀerent stages of development. The matrix can
be myxoid with plexiform vascular pattern. Lipoblastoma
can be confused with intermediate and malignant adipocytic
tumors, including atypical lipomatous tumor/well diﬀeren-
tiated liposarcoma and myxoid liposarcoma [12].
Lipoblastomas usually have simple, pseudodiploid kary-
otypes with structural chromosomal alterations. They are
characterized by rearrangements of 8q11–13 involving the
PLAG1 gene [35–38]. Excess copies of chromosome 8 may4 Journal of Biomedicine and Biotechnology
be found in cases with or without 8q11–13 rearrangements
[10, 39]. Among the several chromosomal aberrations tar-
geting PLAG1, two partner genes have been indentiﬁed:
HAS2 at 8q24 and COL1A2 at 7q22 [40]. Interestingly,
PLAG1rearrangement canbedemonstrated byFISHanalysis
[36, 37, 41–43]. These ﬁndings provide a useful distin-
guishing feature from the cytogenetic and molecular cyto-
genetic aberrations found in myxoid liposarcoma and other
adipocytic tumors.
3.6. Miscellaneous Types of Lipoma. Angiolipoma occurs
chieﬂyasasubcutaneouspainfulnoduleinyoungadults.The
forearm is the most common site, followed by the trunk and
upper arm. Multiple angiolipomas are much more common
than solitary ones. Histologically, angiolipoma is composed
of mature fat cells separated by a branching network of
small vessels. There has been only a single case report of an
angiolipoma with a t(X;12)(p22;p12)[44].
Angiomyolipoma is an uncommon mesenchymal tumor
composed of a variable mixture of mature fat cells, spindle
and epithelioid smooth muscle cells, and abnormal thick-
walled blood vessels. Although most commonly presenting
in the kidney, angiomyolipomas may also occur in the
extrarenal sites. Approximately one-third of patients with
angiomyolipomapresentwithmanifestationsofthetuberous
sclerosis [12]. Immunohistochemically, angiomyolipomas
are characterized by a coexpression of the melanocytic
marker HMB-45 and smooth muscle markers such as
smooth muscle action and muscle-speciﬁc action. Cytoge-
netic studies in renal angiomyolipomas have shown chro-
mosomal aberrations involving trisomy for chromosomes 7
and/or8andrearrangementsofthelongarmofchromosome
12 [45–49]. A CGH study has indicated that chromosomal
imbalancesarecommonandthe5q33-34regionmaycontain
a tumor suppressor gene signiﬁcant in the pathogenesis of
some renal angiomyolipomas [50].
Myelolipoma, most common in the adrenal grand, is
a rare, benign tumor or tumor-like lesion composed of
mature fat cells and haematopoietic elements comprising
myeloid and erythroid cells as well as megakaryocytes. It
can also occur in extra-adrenal soft tissue. There has been
only a single case report of an adrenal myelolipoma with a
t(3;21)(q25;p11)[51].
4.Intermediateand Malignant
AdipocyticTumors
4.1. Atypical Lipomatous Tumor/Well Diﬀerentiated Liposar-
coma. In the current WHO classiﬁcation, atypical lipo-
matous tumor and well diﬀerentiated liposarcoma have
been grouped under the “intermediate (locally aggressive)
malignancy” label [4]. It has been suggested to use the
term “atypical lipomatous tumor” only for the superﬁcial
or subcutaneous locations. Atypical lipomatous tumor/well
diﬀerentiated liposarcoma accounts for about 40%–45%
of all liposarcomas and occurs most frequently in the
thigh, retroperitoneum, and paratesticular/inguinal region
of middle-aged and older individuals [4]. It usually presents
as a painless, slowly growing mass that can attain a very
large size. Histologically, the tumor is composed entirely
or partially of a mature adipocytic proliferation showing
signiﬁcant variation in cell size and at least focal nuclear
atypia in both adipocytes and stromal cells. Four main
subtypes of atypical lipomatous tumor/well diﬀerentiated
liposarcoma are recognized in the current WHO classiﬁca-
tion: adipocytic (lipoma-like), sclerosing, inﬂammatory, and
spindle cell [4] .T h ep r e s e n c eo fm o r et h a no n eh i s t o l o g i c
pattern in the same lesion is common. In some situations,
atypical lipomatous tumor/well diﬀerentiated liposarcoma
may be indistinguishable from benign adipocytic tumors
at the histologic level, and inadequate samples can lead to
misdiagnosis.
Cytogetically, atypical lipomatous tumor/well diﬀeren-
tiated liposarcoma is characterized by the presence of
supernumerary ring and/or giant marker chromosomes,
lacking alpha-satellite centromeric sequences. These ring
and giant marker chromosomes have been observed as the
sole change or concomitant with a few other numerical
or structural aberrations in mostly near-diploid karyotypes.
Random and nonrandom telomeric associations can be
found [52]. FISH and CGH studies have shown that ring
and giant marker chromosomes are composed mainly of
ampliﬁed sequencesfromthe12q13–15region,includingthe
MDM2, CDK4, HMGA2,a n dSAS genes [53–61]. Recently,
Erickson-Johnson et al. [62]d e m o n s t r a t e dt h a tCPM (at
12q15) is coampliﬁed with MDM2 in atypical lipomatous
tumors/well diﬀerentiated liposarcomas. Coampliﬁcation of
1q21–23 involving the COAS genes has also been reported
[63]. This 12q13–15 ampliﬁcation is not observed in benign
adipocytic tumors, and its detection can therefore be used as
anancillary diagnostictechniqueforthediagnosisofatypical
lipomatous tumor/well diﬀerentiated liposarcoma [64, 65].
More importantly, FISH for MDM2 ampliﬁcation can be
performed on nondividing cells from limited tissue samples
and is a more sensitive and speciﬁc adjunctive tool than
MDM2 immunohistochemistry [66].
4.2. Dediﬀerentiated Liposarcoma. Dediﬀerentiated liposar-
coma is a malignant adipocytic tumor showing transition
from atypical lipomatous tumor/well diﬀerentiated liposar-
coma to a nonlipogenic sarcoma of variable histologic grade.
Dediﬀerentiation is thought to be a time-dependent phe-
nomenon that occurs in up to 10% of atypical lipomatous
tumor/well diﬀerentiated liposarcoma. About 90% of dedif-
ferentiated liposarcomas arise “de novo,” while 10% occur in
recurrences [4]. The risk of dediﬀerentiation appears to be
higher in deep-seated lesions. Dediﬀerentiated liposarcoma
occurstypicallyin theretroperitoneumofelderly individuals
and can also aﬀect the extremities. It usually presents as
a painless, large mass, which may be found by chance. In
contrast to atypical lipomatous tumor/well diﬀerentiated
liposarcoma, dediﬀerentiated liposarcoma has a 15%–20%
metastatic rate [67]. Histologically, dediﬀerentiated liposar-
coma is traditionally deﬁned by the association of atypical
lipomatous tumor/well diﬀerentiated liposarcoma areas and
a nonlipogenic component, most often in an abrupt fashion.Journal of Biomedicine and Biotechnology 5
In about 90% of cases, the dediﬀerentiated components have
theappearanceofa high-gradepoorly diﬀerentiatedsarcoma
[12]. Recently, the concept of low-grade dediﬀerentiation
has increasingly been recognized [68]. Due to the histologic
complexity of dediﬀerentiated liposarcoma, many diﬀeren-
tial diagnoses may be raised on the morphologic aspect
alone.
Similar to atypical lipomatous tumor/well diﬀerentiated
liposarcoma,dediﬀerentiatedliposarcomaischaracterizedby
the presence of ring or giant marker chromosomes and dou-
ble minutes. A peculiarity of dediﬀerentiated liposarcoma
might be the presence of multiple abnormal clones [4]. FISH
and CGH studies have demonstrated that ring and giant
marker chromosomes are composed, exclusively or partly,
of ampliﬁed 12q13–15 material, involving MDM2, CDK4,
and HMGA2 [56, 69]. In a previous analysis, we established
the ﬁrst human dediﬀerentiated liposarcoma cell line (FU-
DDLS-1) and showed that giant marker chromosomes
were composed partly of chromosome 12 material [70].
In addition to the 12q13–15 ampliﬁcation, 1p32 and 6q23
ampliﬁcations have been detected by CGH in dediﬀerenti-
ated liposarcomas [71–73]. Array CGH analyses have shown
thatthetargetgenesareJUN inthe1p32band[74]andASK1
in the 6q23 band [75]. Interestingly, co-ampliﬁcations of
1p32 and 6q23 are absent in atypical lipomatous tumor/well
diﬀerentiated liposarcoma, suggesting that CGH is a helpful
diagnostic adjunct in the discrimination between dediﬀer-
entiated liposarcoma and atypical lipomatous tumor/well
diﬀerentiated liposarcoma.
4.3. Myxoid Liposarcoma/Round Cell Liposarcoma. The
WHO Committee combined myxoid and round cell liposar-
comas(previouslytwo distinct subtypes)underthe umbrella
of myxoid liposarcoma [4]. Myxoid liposarcoma, the second
most common subtype of liposarcoma, occurs predomi-
nantly in the extremities of young to middle-aged adults
and has a tendency to recur locally or to metastasize
to unusual sites such as the retroperitoneum, opposite
extremity, and bone. Histologically, the tumor is composed
of a mixture of uniform round- to oval- shaped primitive
mesenchymal cells and a variable number of small lipoblasts
in a prominent myxoid stroma. The presence of round cell
componentis associated with a poor prognosis. Pure myxoid
liposarcoma must be diﬀerentiated from a number of benign
and malignant soft tissue lesions characterized by a myxoid
stroma, such as lipoblastoma, myxoma, myxoﬁbrosarcoma,
low-grade ﬁbromyxoid sarcoma, and extraskeletal myxoid
chondrosarcoma.
Myxoid/round cell liposarcoma is generally associated
with a chromosome number in the diploid range, with only
rare cases being hyperdiploid or near-triploid [76]. It is
characterized by a translocation t(12;16)(q13;p11) in more
than 90% of cases, resulting in an FUS-DDIT3 fusion gene
[77–80]. A variant translocation t(12;22)(q13;q12) has also
been described, resulting in an EWR1-DDIT3 fusion gene
[81–83]. In addition, several nonrandom secondary aber-
rations have been identiﬁed, including del(6q), i(7)(q10),
+8, and der(16)t(1;16) [84–86]. The presence of these
translocations and molecular alterations is highly sensitive
and speciﬁc for myxoid/round cell liposarcoma and is
absent in other liposarcoma subtypes or in other myxoid
soft tissue tumors. Therefore, cytogenetics is an excellent
analytic method for the initial workup of a suspected
myxoid/round cell liposarcoma. Moreover, dual color, break
apartrearrangement probesspanning thegenomicregionsof
DDIT3 (12q13), FUS (16p11), and EWSR1 (22q12) (Abbott
Molecular/Vysis, Des Plaines, IL) are readily available, and
FISH can be used to provide support for the diagnosis of
myxoid/round cell liposarcoma [6, 87]. Conventional and
array CGH studies have shown that genomic imbalances
frequently include gains of 8p21–23, 8q, and 13q in myx-
oid/round cell liposarcomas [88–90].
4.4. Pleomorphic Liposarcoma. Pleomorphic liposarcoma is
a rare, high-grade sarcoma with at least focal adipocytic
diﬀerentiation in the form of pleomorphic lipoblasts. It
occurs predominantly in the extremities of elderly patients
(>50years) andis usually deep-seatedbutmay besuperﬁcial.
In general, pleomorphic liposarcoma has an aggressive
behavior with a 30%–50% metastatic rate and an overall
tumor-associated mortality of 40%–50% [4]. Histologically,
the tumor is composed of pleomorphic multivacuolated
lipoblasts admixed with pleomorphic spindle cells and
multinucleated giant cells. In some cases of pleomorphic
liposarcoma, a small round cell area indistinguishing from
myxoid/round cell liposarcoma is observed with a varying
number of pleomorphic lipoblasts [12].
Pleomorphic liposarcomas are generally associated with
highly complex karyotypes lacking speciﬁc structural or
numerical aberrations [76, 78, 91] .T h ep r e s e n c eo fr i n g s ,
large markers, or double minute chromosomes has been
reported [4]. Recently, Sugita et al. [92]d e m o n s t r a t e d
that the number of DDIT3 split signals in pleomorphic
liposarcomas is extremely scarce compared with that of
myxoid/round cell liposarcoma. Therefore, FISH for DDIT3
rearrangement can play a role in distinguishing between
these two liposarcoma subtypes. Conventional and array
CGH analyses have shown gains of 1p21, 1q21-22, 5p13–
15, 7q22, 9q22-qter, 13q, 17p11.2–12, 20q13, and 22q and
losses of 2q, 3p, 4q, 10q, 11q, 12p13, 13q21, and 14q23-24
[72,88, 89, 93, 94].Interestingly, ampliﬁcation ofthe12q13–
15 region and the MDM2 gene does not occur consistently
in pleomorphic liposarcomas, suggesting that CGH can be
performed to distinguish pleomorphic liposarcoma from
high grade dediﬀerentiated liposarcoma.
4.5. Mixed-Type Liposarcoma. Mixed-type liposarcoma rep-
resents the rarest subtype of liposarcoma and is still con-
sidered a controversial entity. It is deﬁned as a liposarcoma
showing a mixture of features of at least two main subtypes
by histologic examination [4]. The tumor occurs predom-
inantly in retroperitoneal or intra-abdominal locations of
elderly patients. Most recently, de Vreeze et al. [95]p r o p o s e d
that mixed-type liposarcomas should not be regarded as col-
lision tumors, but as an extreme variant of the morphologic
spectrum within a single biologic entity.6 Journal of Biomedicine and Biotechnology
Cytogenetic aberrations in mixed-type liposarcomas
usuallyreﬂectatleastoneofthehistologiccomponentsofthe
tumor. The presence of ring or giant marker chromosomes
has been observed as the sole anomaly or in association with
complex rearrangements [31, 69, 96]. Interestingly, Mentzel
et al. [97] have reported that ampliﬁcation of the MDM2
and CDK4 genes and rearrangements of the DDIT3 and
FUS genes were detected by FISH analysis in the atypical
lipomatous tumor/well diﬀerentiated liposarcoma and myx-
oid/round cell liposarcoma components, respectively.
5.MolecularDiagnostic Algorithmfor
AdipocyticTumors
Molecular genetic testing can be used to distinguish between
(1)lipomaandatypicallipomatoustumor/welldiﬀerentiated
liposarcoma; (2) myxoid liposarcoma and a variety of
myxoid soft tissue tumors including lipoblastoma; and (3)
dediﬀerentiated liposarcoma and pleomorphic liposarcoma
when histologic diagnosis is diﬃcult. In addition, molecular
genetic testing should be considered for recurrent lipomas,
large adipocytic tumors (>15cm) with minimal or no cyto-
logicatypia[98],lesionsarising in rareanatomic locationsor
unusual age groups, or small biopsy specimens.
6.Conclusionsand FutureDirections
Cytogenetics is the most comprehensive laboratory method
for spotting the various translocations and other structural
alterations that characterize adipocytic tumors. In addition,
dramatic advances in molecular cytogenetic technologies
have greatly improved diagnostic accuracy in adipocytic
tumors. In our experience, FISH is very useful in the
diagnosis of adipocytic tumors, which harbor consistent
molecular alterations including nonrandom translocations
and ampliﬁcation of gene regions. Hopefully in the future,
clinicaldecisionswill increasingly bebasedonacombination
ofhistologiccriteriaandspeciﬁcmolecular/cytogeneticaber-
rations. Better understanding of the molecular biology of
adipocytic tumors will undoubtedly lead to the development
of novel therapeutic strategies.
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